Summarized by Masters of Longevity from Longevity Technology.
Voyager will present early clinical data on two tau-targeted therapies at CTAD.
Key Takeaways
- VY1706 is a gene therapy intended to lower tau in Alzheimer's.
- VY7523 is an anti-tau antibody targeting the C-terminal region.
- Findings are early clinical designs and baseline data, not efficacy.
